These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19890210)

  • 1. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.
    Stegall MD; Gloor JM
    Curr Opin Organ Transplant; 2010 Feb; 15(1):8-10. PubMed ID: 19890210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
    Fehr T; Gaspert A
    Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
    Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
    Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated rejection: treatment alternatives and outcomes.
    Singh N; Pirsch J; Samaniego M
    Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
    Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
    Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey.
    Burton SA; Amir N; Asbury A; Lange A; Hardinger KL
    Clin Transplant; 2015 Feb; 29(2):118-23. PubMed ID: 25430052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches to treatment of antibody-mediated rejection.
    Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
    Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
    Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
    Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
    Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
    Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated rejection in kidney transplantation: an update.
    Lucas JG; Co JP; Nwaogwugwu UT; Dosani I; Sureshkumar KK
    Expert Opin Pharmacother; 2011 Mar; 12(4):579-92. PubMed ID: 21294653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of alloantibody-mediated kidney transplant rejection.
    Bartel G; Schwaiger E; Böhmig GA
    Transpl Int; 2011 Dec; 24(12):1142-55. PubMed ID: 21831227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports.
    González-Roncero F; Suñer M; Bernal G; Cabello V; Toro M; Pereira P; Angel Gentil M
    Transplant Proc; 2012 Nov; 44(9):2690-4. PubMed ID: 23146495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.